Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016632 (Fox)
 1,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Treatment of Sprague-Dawley (SD) rats with a dosing regimen of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) maintaining a steady-state liver concentration of 150 ng/g results in enhanced hepatocyte proliferation in the periportal region, but reduced proliferation in the remainder of the hepatic lobule (Fox et al. (1993) Cancer Res., 53, 2265-2271). Here, we report an initial characterization of the actions of TCDD on hepatocyte proliferation by monitoring DNA synthesis in primary hepatocytes isolated from SD rats. TCDD caused a dose-dependent inhibition (EC50 = 10 pM) of DNA synthesis in primary hepatocytes isolated from either male or female SD rats in the presence or absence of known hepatocyte mitogens (epidermal growth factor, hepatocyte growth factor, and transforming growth factor alpha). No change in DNA synthesis was observed at TCDD concentrations less than 1 pM. Initial characterization of the EGF response system in these cells revealed that TCDD did not alter the specific binding of EGF, or the levels of EGF receptor protein measured in intact cells or cell lysates. TCDD-dependent inhibition of DNA synthesis occurred independently of the suppression observed with transforming growth factor-beta 1. Estradiol did not alter DNA synthesis in the presence or absence of TCDD. Taken together, these findings indicate that TCDD suppresses DNA synthesis via a novel pathway that is non-responsive to estradiol, independent of TGF-beta, and does not involve a decreased ability of hepatocytes to recognize (bind) EGF, a prototype mitogen.
 ...
PMID:2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits DNA synthesis in rat primary hepatocytes. 853 40

Traumatic knee injuries frequently involve the disruption of multiple ligaments, such as a complete tear of the medial collateral ligament (MCL) together with a rupture of the anterior cruciate ligament (ACL) (Miyasaka, K., D. M. Daniel, M. L. Stone, and P. Hirshman. Am. J. Knee Surg. 4:3-8, 1991). Despite the high incidence, clinical management of this type of injury is still debated. Laboratory studies have shown that the ACL and MCL share the responsibility of stabilizing the knee, especially in response to valgus and other rotatory torques as well as anterior tibial loads (Inoue, M., E. McGurk-Burleson, J. M. Hollis, and S. L-Y. Woo. Am. J. Sports Med. 15:15-21, 1987; Kanamori, A., M. Sakane, J. Zeminski, T. W. Rudy, and S. L-Y. Woo. J. Ortho. Sci. 5:567-571, 2000; Ma, C. B., C. D. Papageogiou, R. E. Debski, and S. L. Woo. Acta Orthop. Scand. 71:387-393, 2000; Sakane, M., G. A. Livesay, R. J. Fox, T. W. Rudy, T. J. Runco, and S. L-Y. Woo. Knee Surg. Sports Traumatol. Arthrosc. 7:93-97, 1999). When one structure is deficient, the force in the other increases significantly to compensate. The injured ACL does not heal and requires surgical replacement by tissue grafts. On the other hand, after an isolated MCL tear or in a combined MCL and ACL injury, the MCL can heal spontaneously without surgical intervention and can function well in most cases. Nevertheless, the biomechanical and biochemical properties as well as the histomorphological appearance of the healing MCL are substantially different to those of normal tissue (Bray, R. C., D. J. Butterwick, M. R. Daschak, and J. V. Tyberg. J. Orthop. Res. 14:618-625, 1996; Loitz-Ramage, B. J., C. B. Frank, and N. G. Shrive. Clin. Orthop.:272-280, 1997; Weiss, J. A., S. L-Y. Woo, K. J. Ohland, S. Horibe, and P. O. Newton. J. Orthop. Res. 9:516-528, 1991). In an effort to improve the outcome of injuries to these and other ligaments, therapeutic strategies associated with improving biomechanical, biochemical, and histomorphological properties of ligaments have been investigated in recent years. These therapeutic strategies include growth factor stimulation (Conti, N. A., and L. E. Dahners. Presented at Orthopaedic Research Society, San Francisco, CA; Deie, M., T. Marui, C. R. Allen, K. A. Hildebrand, H. I. Georgescu, et al. Mech. Ageing Dev. 97:121-130, 1997), cell therapy (Menetrey, J., C. Kasemkijwattana, C. S. Day, P. Bosch, F. H. Fu, et al. Tissue Eng. 5:435-442, 1999; Watanabe, N., S. L-Y. Woo, C. Papageorgiou, C. Celechovsky, and S. Takai. Microsc. Res. Tech. 58:39-44, 2002), as well as gene stherapy (Nakamura N., D. A. Hart, R. S. Boorman, Y. Kaneda, N. G. Shrive, et al. J. Orthop. Res. 18:517-523, 2000; Shimomura, T., F. Jia, C. Niyibizi, and S. L-Y. Woo. Connect. Tissue Res.:2003). The knowledge gained by studying these therapeutic strategies could potentially be applied to other ligaments and tendons. In this article, antisense gene therapy to alter gene expression by using antisense oligonucleotides will be examined as a possible solution.
 ...
PMID:Functional tissue engineering for ligament healing: potential of antisense gene therapy. 1509 38